Abzyme’s strong suit is its technology to optimize existing antibodies and develop de novo both traditional and modular antibodies with desired attributes. Abzyme can create virtually a limitless variety of bispecific products depending on the therapeutic need, using our single domain antibody generation platform. 

The Company employs a hybrid business model that provides fee-for-service engineering, collaborates with pharmaceutical partners for antibody development including out-licensing its preclinical assets and invests directly in its own drug development programs. For certain programs, we are currently seeking strategic collaborations to jointly advance antibody development and commercialization.